Drugmaker Aurobindo Pharma on Monday said it has entered into licensing and supply agreements with London-based pharmaceutical giant AstraZeneca to supply several solid dosage and sterile products for emerging markets.
The agreements will support AstraZeneca's investment in Branded Generics sold in emerging markets. These products fall under a broad range of important therapeutic segments such as Anti-Infective, Cardiovascular System and Central Nervous System.
However, the financial terms were not disclosed. Commenting on the alliance, P V Ramprasad Reddy, Chairman, Aurobindo Pharma said, "Aurobindo's proven track record in building strong, collaborative working relationships is a key driver for these strategic agreements with AstraZeneca which will accelerate our growth plans and support our earnings."
Kaushik Banerjee, Head of Branded Generics Operations at AstraZeneca said, "these agreements will enable us to extend the range of branded medicines we are able to offer patients in emerging markets, where we see continued opportunities to grow our business."
